Cargando…
PVT1 Exon 9: A Potential Biomarker of Aggressive Prostate Cancer?
Prostate cancer (PCa) is the most commonly diagnosed cancer as well as the greatest source of cancer-related mortality in males of African ancestry (MoAA). Interestingly, this has been shown to be associated with single nucleotide polymorphisms around regions 2 and 3 of the 8q24 human chromosomal re...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4730403/ https://www.ncbi.nlm.nih.gov/pubmed/26703666 http://dx.doi.org/10.3390/ijerph13010012 |
_version_ | 1782412392230027264 |
---|---|
author | Ilboudo, Adeodat Chouhan, Jyoti McNeil, Brian K. Osborne, Joseph R. Ogunwobi, Olorunseun O. |
author_facet | Ilboudo, Adeodat Chouhan, Jyoti McNeil, Brian K. Osborne, Joseph R. Ogunwobi, Olorunseun O. |
author_sort | Ilboudo, Adeodat |
collection | PubMed |
description | Prostate cancer (PCa) is the most commonly diagnosed cancer as well as the greatest source of cancer-related mortality in males of African ancestry (MoAA). Interestingly, this has been shown to be associated with single nucleotide polymorphisms around regions 2 and 3 of the 8q24 human chromosomal region. The non-protein coding gene locus Plasmacytoma Variant Translocation 1 (PVT1) is located at 8q24 and is overexpressed in PCa and, therefore, is also a candidate biomarker to explain the well-known disparity in this group. PVT1 has at least 12 exons that make separate transcripts which may have different functions, all of which are at present unknown in PCa. Our aim was to determine if any PVT1 transcripts play a role in aggressiveness and racial disparity in PCa. We used a panel of seven PCa cell lines including three derived from MoAA. Ribonucleic acid extraction, complementary deoxyribonucleic acid synthesis, and quantitative polymerase chain reaction (qPCR) were performed to evaluate expression of all 12 PVT1 exons. Each qPCR was performed in quadruplicates. At least four separate qPCR experiments were performed. Expression of PVT1 exons was inconsistent except for exon 9. There was no significant difference in exon 9 expression between cell lines derived from Caucasian males (CM), and an indolent cell line derived from MoAA. However, exon 9 expression in the aggressive MDA PCa 2b and E006AA-hT cell lines derived from MoAA was significantly higher than in other cell lines. Consequently, we observed differential expression of exon 9 of PVT1 in a manner that suggests that PVT1 exon 9 may be associated with aggressive PCa in MoAA. |
format | Online Article Text |
id | pubmed-4730403 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-47304032016-02-11 PVT1 Exon 9: A Potential Biomarker of Aggressive Prostate Cancer? Ilboudo, Adeodat Chouhan, Jyoti McNeil, Brian K. Osborne, Joseph R. Ogunwobi, Olorunseun O. Int J Environ Res Public Health Article Prostate cancer (PCa) is the most commonly diagnosed cancer as well as the greatest source of cancer-related mortality in males of African ancestry (MoAA). Interestingly, this has been shown to be associated with single nucleotide polymorphisms around regions 2 and 3 of the 8q24 human chromosomal region. The non-protein coding gene locus Plasmacytoma Variant Translocation 1 (PVT1) is located at 8q24 and is overexpressed in PCa and, therefore, is also a candidate biomarker to explain the well-known disparity in this group. PVT1 has at least 12 exons that make separate transcripts which may have different functions, all of which are at present unknown in PCa. Our aim was to determine if any PVT1 transcripts play a role in aggressiveness and racial disparity in PCa. We used a panel of seven PCa cell lines including three derived from MoAA. Ribonucleic acid extraction, complementary deoxyribonucleic acid synthesis, and quantitative polymerase chain reaction (qPCR) were performed to evaluate expression of all 12 PVT1 exons. Each qPCR was performed in quadruplicates. At least four separate qPCR experiments were performed. Expression of PVT1 exons was inconsistent except for exon 9. There was no significant difference in exon 9 expression between cell lines derived from Caucasian males (CM), and an indolent cell line derived from MoAA. However, exon 9 expression in the aggressive MDA PCa 2b and E006AA-hT cell lines derived from MoAA was significantly higher than in other cell lines. Consequently, we observed differential expression of exon 9 of PVT1 in a manner that suggests that PVT1 exon 9 may be associated with aggressive PCa in MoAA. MDPI 2015-12-22 2016-01 /pmc/articles/PMC4730403/ /pubmed/26703666 http://dx.doi.org/10.3390/ijerph13010012 Text en © 2015 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons by Attribution (CC-BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Ilboudo, Adeodat Chouhan, Jyoti McNeil, Brian K. Osborne, Joseph R. Ogunwobi, Olorunseun O. PVT1 Exon 9: A Potential Biomarker of Aggressive Prostate Cancer? |
title | PVT1 Exon 9: A Potential Biomarker of Aggressive Prostate Cancer? |
title_full | PVT1 Exon 9: A Potential Biomarker of Aggressive Prostate Cancer? |
title_fullStr | PVT1 Exon 9: A Potential Biomarker of Aggressive Prostate Cancer? |
title_full_unstemmed | PVT1 Exon 9: A Potential Biomarker of Aggressive Prostate Cancer? |
title_short | PVT1 Exon 9: A Potential Biomarker of Aggressive Prostate Cancer? |
title_sort | pvt1 exon 9: a potential biomarker of aggressive prostate cancer? |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4730403/ https://www.ncbi.nlm.nih.gov/pubmed/26703666 http://dx.doi.org/10.3390/ijerph13010012 |
work_keys_str_mv | AT ilboudoadeodat pvt1exon9apotentialbiomarkerofaggressiveprostatecancer AT chouhanjyoti pvt1exon9apotentialbiomarkerofaggressiveprostatecancer AT mcneilbriank pvt1exon9apotentialbiomarkerofaggressiveprostatecancer AT osbornejosephr pvt1exon9apotentialbiomarkerofaggressiveprostatecancer AT ogunwobiolorunseuno pvt1exon9apotentialbiomarkerofaggressiveprostatecancer |